MedPath

Matinas Biopharma, Inc.

🇺🇸United States
Ownership
Subsidiary
Employees
-
Market Cap
$23.4M
Website

Clinical Trials

2

Active:0
Completed:1

Trial Phases

2 Phases

Phase 1:1
Phase 3:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials

Phase 1
1 (50.0%)
Phase 3
1 (50.0%)

Safety and Efficacy of MAT9001(Omega-3-pentaenoic Acid) in Subjects With Triglycerides ≥500 mg/dL and <2000 mg/dL

Phase 3
Withdrawn
Conditions
Severe Hypertriglyceridemia
Interventions
Drug: Placebo
Drug: MAT9001 (omega-3 pentaenoic acid)
First Posted Date
2020-12-10
Last Posted Date
2021-09-16
Lead Sponsor
Matinas Biopharma, Inc
Registration Number
NCT04662528

A PK and PD Study of Two Formulations of Omega-3 One Gram Capsules

Phase 1
Completed
Conditions
Hypertriglyceridemia
Interventions
First Posted Date
2014-12-05
Last Posted Date
2020-10-12
Lead Sponsor
Matinas Biopharma, Inc
Target Recruit Count
48
Registration Number
NCT02310022
Locations
🇨🇦

Pharma Medica Reserach Inc, Toronto, Ontario, Canada

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.